3-hydroxylidocaine has been researched along with fluvoxamine in 2 studies
| Studies (3-hydroxylidocaine) | Trials (3-hydroxylidocaine) | Recent Studies (post-2010) (3-hydroxylidocaine) | Studies (fluvoxamine) | Trials (fluvoxamine) | Recent Studies (post-2010) (fluvoxamine) |
|---|---|---|---|---|---|
| 10 | 2 | 1 | 2,051 | 518 | 434 |
| Protein | Taxonomy | 3-hydroxylidocaine (IC50) | fluvoxamine (IC50) |
|---|---|---|---|
| D | Rattus norvegicus (Norway rat) | 0.54 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.54 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.54 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.54 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.0038 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 0.54 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.54 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 3.1 | |
| Transporter | Rattus norvegicus (Norway rat) | 0.54 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Backman, JT; Kivistö, KT; Neuvonen, PJ; Taavitsainen, P; Wang, JS; Wen, X | 1 |
| Isohanni, MH; Neuvonen, PJ; Olkkola, KT | 1 |
1 trial(s) available for 3-hydroxylidocaine and fluvoxamine
| Article | Year |
|---|---|
Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine.
Topics: Administration, Oral; Adult; Anesthetics, Local; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Erythromycin; Female; Fluvoxamine; Half-Life; Humans; Lidocaine; Male; Metabolic Clearance Rate; Nausea | 2006 |
1 other study(ies) available for 3-hydroxylidocaine and fluvoxamine
| Article | Year |
|---|---|
Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro.
Topics: Anesthetics, Local; Autopsy; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erythromycin; Fluvoxamine; Humans; In Vitro Techniques; Ketoconazole; Lidocaine; Male; Microsomes, Liver; Middle Aged; Mixed Function Oxygenases | 1999 |